Preclinical Characterization of CK-4021586, a New Class of Cardiac Myosin Inhibitors for the Treatment of Hypertrophic Cardiomyopathy

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Pharmacokinetics of a Single Dose of Aficamten (CK-274) on Cardiac Contractility in a A31P MYBPC3 Hypertrophic Cardiomyopathy Cat Model

Aficamten, a Selective Small-Molecule Cardiac Myosin Inhibitor for the Potential Treatment of Hypertrophic Cardiomyopathy

A Novel Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics

Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Discovery of CK-274: A novel, small molecule, cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathies (HCM)

The Cardiac Myosin Inhibitor, CK-3772271, Attenuates Cardiac Fibrosis and Diastolic Dysfunction in the Dahl/Salt Sensitive Rat Model of Heart Failure with Preserved Ejection Fraction

Pharmacodynamic Effects of a Single Dose of CK-3773274 in Cats with Hypertrophic Cardiomyopathy